Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

Imagem de Miniatura
Arquivos
art_WILDER-SMITH_Deliberations_of_the_Strategic_Advisory_Group_of_Experts_2019.PDF (97.77 KB)
Citações na Scopus
110
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
WILDER-SMITH, Annelies
HOMBACH, Joachim
FERGUSON, Neil
SELGELID, Michael
BRIEN, Kate O.
VANNICE, Kirsten
BARRETT, Alan
FERDINAND, Elizabeth
FLASCHE, Stefan
GUZMAN, Maria
Citação
LANCET INFECTIOUS DISEASES, v.19, n.1, p.E31-E38, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/30022
Referências
  1. Alvarez M, 2006, AM J TROP MED HYG, V75, P1113, DOI 10.4269/ajtmh.2006.75.1113
  2. Anderson KB, 2018, LANCET INFECT DIS, V18, pE333, DOI 10.1016/S1473-3099(18)30126-9
  3. [Anonymous], 2016, Wkly Epidemiol Rec, V91, P349
  4. [Anonymous], 2016, Wkly Epidemiol Rec, V91, P266
  5. [Anonymous], 2018, BACKGR PAP DENG VACC
  6. Arien KK, 2018, LANCET GLOB HEALTH, V6, pe380
  7. Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
  8. Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
  9. [Dengue vaccine 91], 2016, WKLY EPIDEMIOL REC, P349
  10. Duclos P, 2012, VACCINE, V31, P12, DOI 10.1016/j.vaccine.2012.02.041
  11. Ferguson NM, 2016, SCIENCE, V353, P1033, DOI 10.1126/science.aaf9590
  12. Ferguson RW, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw010
  13. Flasche S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002181
  14. Glass RI, 2006, NEW ENGL J MED, V354, P75, DOI 10.1056/NEJMe058285
  15. Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
  16. Imai N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004833
  17. Imai N, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003719
  18. Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062
  19. Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
  20. Katzelnick LC, 2017, VACCINE, V35, P4659, DOI 10.1016/j.vaccine.2017.07.045
  21. L'Azou M, 2016, NEW ENGL J MED, V374, P1155, DOI 10.1056/NEJMoa1503877
  22. Lalani T, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw043
  23. Nascimento EJM, 2018, J VIROL METHODS, V257, P62, DOI 10.1016/j.jviromet.2018.04.009
  24. Neuberger A, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw003
  25. Osorio JE, 2015, VACCINE, V33, P7112, DOI 10.1016/j.vaccine.2015.11.022
  26. Riddell A, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax015
  27. Rosenbaum L, 2018, NEW ENGL J MED, V379, P305, DOI 10.1056/NEJMp1804094
  28. Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
  29. Sanofi Pasteur, SAN UPD INF DENG VAC
  30. Selgelid MJ, 2009, PUBLIC HEALTH ETH-UK, V2, P195, DOI 10.1093/phe/php018
  31. Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
  32. Turner HC, 2018, T ROY SOC TROP MED H, V112, P369, DOI 10.1093/trstmh/try057
  33. Vannice KS, 2018, VACCINE, V36, P3411, DOI 10.1016/j.vaccine.2018.02.062
  34. Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
  35. Vongpunsawad S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180560
  36. Whitehead SS, 2016, EXPERT REV VACCINES, V15, P509, DOI 10.1586/14760584.2016.1115727
  37. WHO, 2017, INF VACC PROGR GUID
  38. WHO, 2016, BACKGR PAP DENG VACC
  39. WHO, 2018, SAGE M REP APR 2018
  40. WHO, 2011, GUID QUAL SAF EFF DE
  41. WHO, 2017, REC SAGE WORK GROUP
  42. WHO, 2018, M STRAT ADV GROUP EX
  43. Wichmann O, VACCINE
  44. Wilder-Smith A., 2016, LANCET INFECT DIS, V17, pe101
  45. Wilder-Smith A, 2016, J INFECT DIS, V214, P1796, DOI 10.1093/infdis/jiw341

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03